Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme

Life Sciences Blog

Posted on 02 June 2009 – 17:10 by Alfie

Story Summary:…All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmo, Sweden….We are very gratified to have been chosen to provide the worlds leading HPV vaccine to the national vaccination programme in Norway….1,2,3 New data from Australia presented at IPC demonstrated a strong early impact of four-type HPV vaccination….All available clinical data suggest that Gardasil(r) will provide long-term protection….The vaccine has demonstrated to induce immune memory which experts consider a hall mark of long-term protection….Nine out of ten physicians in Western Europe choose Gardasil(r) when given a choice in prescribing HPV vaccination….The indication is based on the demonstration of efficacy of Gardasil(r) in adult females 16 to 26 years of age and on the demonstration of immunogenicity of Gardasil in 9- to 15-year old children and adolescents….Protective efficacy has not been evaluated in males (see section 5….The use of Gardasil(r) should be in accordance with official recommendations….About Sanofi Pasteur MSD Sanofi Pasteur MSD is a joint venture between sanofi pasteur, the vaccine division of sanofi-aventis,and Merck & Co. , Inc. Combining innovation and expertise, Sanofi Pasteur MSD is the only company in Europe dedicated exclusively to vaccines….Sanofi Pasteur MSD is able to draw on the research expertise of Sanofi Pasteur and Merck & Co. , Inc. , together with their teams throughout the world, to focus on the development of new vaccines for Europe, which aim to extend protection to other diseases and perfect existing vaccines in order to improve the acceptability, efficacy and tolerability of vaccination….Smith JS et al. Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions: A meta-analysis update….Australia has distributed Gardasil(r) since April 2007 free of charge to school girls between 12 and 18 years….The total coverage rate in the region where the study took place in these target groups is between 65 % and 75 %….Rowhani-Rahbar, A et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine….For more information, please read our terms and conditions….Read the Full Story


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.